Latest Breaking News On - Katelin roberts - Page 3 : comparemela.com

 E-Mail Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah, one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease. The partnership intends to implement RenalytixAI s in vitro diagnostic platform, KidneyIntelX, in combination with a range of advanced clinical management solutions to optimize patient care and drive towards improved outcomes system-wide at University of Utah Health, which serves millions of patients in six states. KidneyIntelX is designed for the identification of adults with early-stage chronic kidney disease and diabetes who are at risk for progressive kidney function decline or kidney failure.

United statesUniversity of utahKatelin robertsJames mcculloughJohn inadomiKeith marmerCenters for diseaseDepartment of internal medicineUniversity of utah healthUniversity of utah research parkOutreach technologyUniversity of utah school medicineUtah healthInternal medicineUtah schoolResearch park